Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAA50 | Q9GZZ1 | 2/20 | 0.89 |
| ▸ | CHAT | P28329 | 2/20 | 0.85 |
| ▸ | EP300 | Q09472 | 3/20 | 0.84 |
| ▸ | AURKA | O14965 | 2/20 | 0.84 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.84 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.84 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16983169 | 1.00 | NAA50 (0.89) | NAA50CHATEP300AURKAKAT5 | |
| SCHEMBL21874989 | 1.00 | NAA50 (0.89) | NAA50CHATEP300AURKAKAT5 | |
| SCHEMBL25996812 | 1.00 | NAA50 (0.89) | NAA50CHATEP300AURKAKAT5 | |
| SCHEMBL28097736 | 1.00 | NAA50 (0.89) | NAA50CHATEP300AURKAKAT5 | |
| SCHEMBL120458 | 1.00 | NAA50 (0.89) | NAA50CHATEP300AURKAKAT5 | |
| Lithium SCHEMBL29390807 | 0.99 | NAA50 (0.88) | NAA50CHATEP300AURKAKAT5 | |
| Lithium SCHEMBL18249414 | 0.99 | NAA50 (0.88) | NAA50CHATEP300AURKAKAT5 | |
| SCHEMBL28324180 | 0.98 | NAA50 (0.86) | NAA50CHATEP300AURKAKAT5 | |
| Isobutyraldehyde SCHEMBL28444156 | 0.97 | NAA50 (0.84) | NAA50CHATEP300AURKAKAT5 | |
| SCHEMBL28487648 | 0.97 | NAA50 (0.84) | NAA50CHATEP300AURKAKAT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1714 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713320-A2 | BCAT2 INHIBITORS | Agios Pharmaceuticals, Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| EP-4662192-A1 | MICROORGANISMS AND METHODS FOR REDUCING BY-PRODUCTS | Genomatica, Inc. (US) | 2025-12-17 | — | — | EP | claimed |
| EP-4623074-A1 | RECOMBINANT POLYPEPTIDES WITH PRENYLTRANSFERASE ACTIVITY FOR BIOSYNTHESIS OF CANNABINOIDS AND HOP COMPOUNDS | Epimeron USA, Inc. (US) | 2025-10-01 | — | — | EP | claimed |
| US-20250270598-A1 | RECOMBINANT POLYPEPTIDES WITH PRENYLTRANSFERASE ACTIVITY FOR BIOSYNTHESIS OF CANNABINOIDS AND HOP COMPOUNDS | EPIMERON USA, INC. (US) | 2025-08-28 | — | — | US | claimed |
| EP-4565706-A1 | MICROBIAL PRODUCTION OF MONOMERS FOR RECYCLING OF PLASTIC POLYMERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-06-11 | — | — | EP | claimed |
| WO-2024030662-A9 | MICROBIAL PRODUCTION OF MONOMERS FOR RECYCLING OF PLASTIC POLYMERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-02-27 | — | — | WO | claimed |
| CN-110291194-B | Method for microbial production of 8-methylnonanoic acid | 科纳根公司 | 2024-11-22 | — | — | CN | claimed |
| WO-2024238820-A2 | BCAT2 INHIBITORS | AGIOS PHARMACEUTICALS, INC. (US) | 2024-11-21 | — | — | WO | claimed |
| US-20240366543-A1 | METHODS OF TREATING METHYLMALONIC ACIDEMIA AND PROPIONIC ACIDEMIA | HEMOSHEAR THERAPEUTICS INC (US) | 2024-11-07 | — | — | US | claimed |
| EP-4430036-A2 | BCAT2 INHIBITORS | Agios Pharmaceuticals, Inc. (US) | 2024-09-18 | — | — | EP | claimed |
| EP-1948814-A2 | FERMENTIVE PRODUCTION OF FOUR CARBON ALCOHOLS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2008-07-30 | — | — | EP | claimed |
| US-20070190605-A1 | GENE PRODUCTS OF BACILLUS LICHENIFORMIS WHICH FORM ODOROUS SUBSTANCES AND IMPROVED BIOTECHNOLOGICAL PRODUCTION METHODS BASED THEREON | BASF SE (DE) | 2007-08-16 | — | — | US | claimed |
| WO-2007050671-A2 | FERMENTIVE PRODUCTION OF FOUR CARBON ALCOHOLS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2007-05-03 | — | — | WO | claimed |
| US-20070092957-A1 | producing isobutanol by the fermentive growth of a recombinant bacteria expressing a isobutanol biosynthetic pathway | GEVO, INC. | 2007-04-26 | — | — | US | claimed |
| EP-1761628-A2 | NOVEL GENE PRODUCTS OF BACILLUS LICHENIFORMIS WHICH FORM ODOROUS SUBSTANCES AND IMPROVED BIOTECHNOLOGICAL PRODUCTION METHODS BASED THEREON | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2007-03-14 | — | — | EP | claimed |
| WO-2006000343-A2 | NOVEL GENE PRODUCTS OF BACILLUS LICHENIFORMIS WHICH FORM ODOROUS SUBSTANCES AND IMPROVED BIOTECHNOLOGICAL PRODUCTION METHODS BASED THEREON | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2006-01-05 | — | — | WO | claimed |
| US-6531299-B1 | Incubating proteins comprising polyketide synthase, butyryl Coenzyme A, and thioester of butyric acid | STANFORD UNIVERSITY | 2003-03-11 | — | — | US | claimed |
| EP-1098630-A2 | COMPOSITION FOR ENHANCING EPIDERMAL LIPID PRODUCTION | Biomed Research and Technologies, Inc. (US) | 2001-05-16 | — | — | EP | claimed |
| US-6149924-A | FOR TOPICAL APPLICATION | BIOMED RESEARCH & TECHNOLOGIES, INC. (US) | 2000-11-21 | — | — | US | claimed |
| WO-2000004870-A2 | COMPOSITION FOR ENHANCING EPIDERMAL LIPID PRODUCTION | BIOMED RESEARCH AND TECHNOLOGIES, INC. (US) | 2000-02-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366543-A1 | METHODS OF TREATING METHYLMALONIC ACIDEMIA AND PROPIONIC ACIDEMIA | MMAB, OTC, ME2 | NAA50 3556/4885CHAT 1146/4885EP300 2717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.